Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Abroad (travel likely)RecruitingPHASE2

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

M D Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Muzaffar Qazilbash, MD) · mqazilba@mdanderson.org · 713-745-3458
Contact: Principal Investigator (Muzaffar Qazilbash, MD)

Study leads

Muzzaffar Qazilbash, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Relapse Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Madison, United States

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Multiple Myeloma

IsraelRecruitingPHASE3

Jupiter, United States · Basking Ridge, United States

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Denver, United States

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia (PCL)

Abroad (travel likely)RecruitingPHASE2

Changchun, China